BidaskClub cut shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a hold rating in a research report report published on Thursday morning, BidAskClub reports.

Several other equities research analysts also recently issued reports on the stock. ValuEngine raised shares of Xylem from a hold rating to a buy rating in a research report on Friday, June 21st. Canaccord Genuity downgraded shares of Magellan Aerospace from a buy rating to a hold rating and lowered their price objective for the stock from C$21.00 to C$20.00 in a research report on Monday, May 13th. Raymond James reissued a buy rating on shares of Canadian Natural Resources in a research report on Friday, May 10th. Cantor Fitzgerald reissued a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a research report on Thursday, May 9th. Finally, TheStreet raised shares of TerraForm Power from a c rating to a b- rating in a research report on Tuesday, March 19th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $84.50.

Shares of NASDAQ:ANIP opened at $81.36 on Thursday. ANI Pharmaceuticals has a 52 week low of $36.92 and a 52 week high of $84.10. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The company has a market capitalization of $980.06 million, a P/E ratio of 17.38 and a beta of 2.25. The firm has a 50 day moving average price of $75.21.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.25. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. The firm had revenue of $52.90 million during the quarter, compared to the consensus estimate of $50.57 million. During the same quarter in the prior year, the firm earned $1.32 earnings per share. The business’s quarterly revenue was up 13.8% on a year-over-year basis. As a group, equities analysts forecast that ANI Pharmaceuticals will post 5.57 earnings per share for the current year.

In other ANI Pharmaceuticals news, Director David Nash bought 1,445 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, May 24th. The stock was acquired at an average price of $68.76 per share, for a total transaction of $99,358.20. Following the completion of the acquisition, the director now owns 5,236 shares of the company’s stock, valued at approximately $360,027.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Arthur Przybyl sold 30,000 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $70.07, for a total transaction of $2,102,100.00. Following the transaction, the insider now owns 222,994 shares of the company’s stock, valued at approximately $15,625,189.58. The disclosure for this sale can be found here. Insiders have sold 50,911 shares of company stock valued at $3,585,114 in the last three months. 24.70% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. First Trust Advisors LP boosted its holdings in ANI Pharmaceuticals by 1.2% during the first quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock worth $1,067,000 after purchasing an additional 179 shares during the last quarter. Texas Permanent School Fund lifted its stake in ANI Pharmaceuticals by 3.8% in the first quarter. Texas Permanent School Fund now owns 5,633 shares of the specialty pharmaceutical company’s stock valued at $397,000 after acquiring an additional 206 shares during the last quarter. Comerica Bank lifted its stake in ANI Pharmaceuticals by 3.1% in the first quarter. Comerica Bank now owns 8,239 shares of the specialty pharmaceutical company’s stock valued at $570,000 after acquiring an additional 248 shares during the last quarter. THB Asset Management lifted its stake in ANI Pharmaceuticals by 1.1% in the first quarter. THB Asset Management now owns 25,431 shares of the specialty pharmaceutical company’s stock valued at $1,793,000 after acquiring an additional 275 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in ANI Pharmaceuticals by 0.8% in the fourth quarter. Principal Financial Group Inc. now owns 67,326 shares of the specialty pharmaceutical company’s stock valued at $3,031,000 after acquiring an additional 529 shares during the last quarter. Institutional investors and hedge funds own 63.92% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

See Also: What is a Fiduciary?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.